Dedicated to Serving You

Firm Overview

Gregg Goldfarb of Gregg M. Goldfarb, LLP has over 25 years of experience representing clients, including individuals, small businesses, and medical professionals. His practice provides dedicated representation for clients in cases that include accidents, defective products, insurance claims, PIP insurance claims, civil rights, and whistleblower claims. Representation is focused on suiting your needs and using his knowledge and experience to help you pursue compensation for your injuries. Consultations are always free, and you pay nothing unless there is a settlement or victory that leads to a payout for your claim.

Current Defective Products & Mass Tort Cases

3M Earplugs

From 2003-2015, all branches of the US military issued 3M Combat earplugs to soldiers. A design defect in the earplugs made them ineffective, and thousands of soldiers were not afforded the hearing protection they required. The earplugs were not shaped correctly and became unsealed when placed in the ear. Users of the earplugs were not aware of the ineffectiveness of the product and relied on the 3M Combat earplugs to protect their hearing. Veterans and active military personnel may have sustained hearing loss or damage as a result of the defective earplugs.

Hernia Mesh

A hernia occurs when an organ, intestine, or fatty tissue squeezes through a weak area or hole in the muscle. Hernia mesh is used by surgeons to repair the hernia. The mesh can also be used for the treatment of surgical wounds. Several types of hernia mesh have been linked to serious complications for patients, including allergic reactions, mesh erosion or failure, abdominal pain, organ perforation, bowel obstruction, and intestinal fistulas. Some manufacturers of hernia mesh failed to warn patients of the risks associated with the use of the product. If you’ve been injured due to the use of hernia mesh, you may have a product liability claim.

Juul E-Cigarettes

Juul is the top-selling brand of e-cigarettes in the United States. Now the Centers for Disease Control is warning that using Juul e-cigarettes can be dangerous to consumers, especially young people. Because of the high level of nicotine salts contained in Juul e-cigarettes, the product is extremely dangerous for the brains of teenagers and young adults.

While Juul was intended to be used by smokers who were trying to quit nicotine, manufacturers began marketing the product to teenagers who were not even smokers. It led consumers to believe that Juul was a safe alternative to smoking. Much of this marketing was directed toward young adults. The marketing campaigns, coupled with the availability of different flavors of e-cigarettes, led to many teens and young people using the product even though they had never smoked before. These individuals are now fighting addiction and the long-term health effects of Juul e-cigarettes.


Opioid addiction has had a devastating effect on millions of families across the country. The manufacturers and distributors of opioids such as OxyContin and Percocet have repeatedly downplayed the addictive nature of their product, and opioids should never have been prescribed on a long-term basis. Opioid addiction can cause serious health problems and can lead to complicated and expensive rehabilitation, lost wages and mental health issues. Individuals who have been injured by opioid addiction deserve compensation for what they lost.


Monsanto’s Roundup is one of the most widely-used weed killers in the world. Recent studies now show that Roundup may cause cancer in people who use Roundup either on a regular basis or occasionally around the home. Monsanto has known for years about the link between Roundup and non-Hodgkin’s lymphoma but has continued to market its product as safe for consumers. Three verdicts have now awarded victims substantial damages, finding that Roundup was a contributing factor to cancer.


Xeljanz is a popular drug used to treat rheumatoid arthritis, ulcerative colitis, and psoriatic arthritis. In 2019, the FDA approved a black box warning for the product warning consumers of the risk of blood clots and potential death for users of the drug. Studies show that Xeljanz, at higher dosages, places users at an increased risk of developing dangerous blood clots. There is evidence that manufacturer Pfizer was aware of the safety issues at higher dosages and yet continued to market the product as safe.